Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Manuel Llobet | CEO & Executive Director | 484.51k | 29.92k | 1965 |
| Dr. Shaun Antony Furlong | CFO & Executive Director | 207.93k | -- | 1976 |
| Dr. Murray Skinner | Chief Scientific Officer | -- | -- | -- |
| Ms. Sue Baker | Head of Human Resources | -- | -- | -- |
| Simon Piggott | Head of Clinical Science | -- | -- | -- |
| Alan Bullimore | Head of Communication & Market Development | -- | -- | -- |
| Mr. Russell Picket | Group Financial Controller | -- | -- | -- |
| Karley Charlotte Mouatt Cheesman | Company Secretary | -- | -- | -- |
| Mr. Matthew Heath | Principal Scientist | -- | -- | -- |
Allergy Therapeutics plc
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. The company operates in Germany, Austria, Netherlands, Switzerland, Italy, Spain, and internationally, as well as the United Kingdom. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
Corporate Governance
Upcoming Events
March 25, 2025 at 7:30 AM UTC - March 31, 2025 at 7:30 AM UTC
Allergy Therapeutics plc Earnings Date
Recent Events
Recent Events Information Not Available